BenevolentAI, a leading London-based biotechnology company, announced a significant leadership change as CEO Joerg Moeller stepped down with immediate effect. This development, revealed on Thursday, marks yet another shift in the company's executive ranks since it went public in early 2022 via a special purpose acquisition company (SPAC).
Joerg Moeller, who joined BenevolentAI in January, had previously served as the global Research and Development head for Leo Pharma. He took over the CEO role from Joanna Shields, but now, less than ten months into his tenure, he has departed without a specified reason from the company. There is no successor named for Moeller, although the company stated that founder Ken Mulvany has taken on the role of executive chairman. Mulvany, who returned to the board in May amid strategic changes at the board level, expressed optimism about the company's future, stating that they have only begun to harness their platform's potential.
BenevolentAI, founded in 2013, has been at the forefront of integrating artificial intelligence into biotechnology, positing that AI could dramatically reduce preclinical costs and accelerate the drug development process. Despite these promises, the company has faced challenges, with its stock price plummeting over 90% since going public. A mid-stage trial of its lead drug candidate for eczema did not meet expectations last year, prompting the discontinuation of the programme.
The ambitious growth projections BenevolentAI presented to investors—aiming to expand its drug development pipeline from 12 programmes in 2021 to more than 50 by 2026, and eventually reaching 87 by 2030—have not materialised as expected. Currently, the company's pipeline consists of just nine projects, with one in clinical trials and eight still in preclinical stages. Furthermore, the company has significantly reduced its R&D and overall expenditure, including layoffs in May last year and this April.
The company's sole clinical-stage drug, which demonstrated positive outcomes in a Phase 1 study involving healthy volunteers earlier this year, is the focus of ongoing out-licensing and partnership discussions. This aligns with BenevolentAI’s strategic shift towards collaboration in order to navigate its current challenges.
BenevolentAI is not alone in its struggles. Many biotech firms that initially embraced AI-driven approaches to drug development have faced similar setbacks. Exscientia recently decided to merge with Recursion, while Atomwise saw the departure of its founding CEO, Abe Heifets, without a public announcement of a successor. These developments indicate the broader difficulties faced within the biotech sector, as AI-driven technologies have yet to fully deliver on their transformative potential in clinical settings.
Source: Noah Wire Services